FADD Protein for the Early Diagnosis of Rheumatoid Arthritis
Abstract
Objective FADD (Fas‐Associated Death Domain) protein in patients’ serum and synovial fluid could be a biomarker of inflammation in rheumatic diseases. We tested whether the baseline serum FADD level would be a predictive factor for meeting the American College of Rheumatology (ACR)/EULAR 2010 criteria for rheumatoid arthritis (RA) in order to facilitate the early diagnosis of RA. Methods We measured FADD by enzyme‐linked immunosorbent assay in the sera from 659 patients with early arthritis from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort (at least two swollen joints for more than six weeks and less than six months, no previous exposure to glucocorticoids or disease‐modifying antirheumatic drugs). Patients were eligible for inclusion in the cohort if they had a definitive or probable clinical diagnosis of RA or a diagnosis of undifferentiated arthritis (UA) with a potential for progressing to RA, according to the 2010 ACR/EULAR criteria for RA. Results At inclusion, serum FADD protein was detected in 501 of 659 (76%) patients (range 0–1,503 ng/mL) and levels were independent of patient age and sex. Statistically significant higher levels of FADD were detected in the serum from patients with diagnosed RA at inclusion or who were diagnosed with RA thereafter, than from patients with UA. Receiver operating characteristic curve analysis indicated that a FADD >8 ng/mL had the best sensitivity (50.95%) and specificity (85.71%) for the diagnosis of RA. Moreover, FADD levels were positively associated with anti–citrullinated protein antibody (ACPA), rheumatoid factors, proinflammatory interleukin‐1β (IL‐1β), IL‐6 and IL‐2, and APRIL, a marker of B lymphocyte activation. Conclusion Baseline serum FADD level measurement appeared as a helpful biomarker for the early diagnosis of RA, particularly in patients who were ACPA negative.
Related
- Joint–brain communication in rheumatoid arthritis: glial mechanisms, pain phenotypes, and translational evidence
- Histone lactylation in fibroblast-like synoviocytes drives CXCL1-mediated immune cell recruitment in rheumatoid arthritis
- Serum Calprotectin as predictor of Rheumatoid Arthritis disease severity and Mortality
- Identification of a shared PAX5-mediated B-cell regulatory axis in inflammatory bowel disease and rheumatoid arthritis
- Thymic CT attenuation score in SAPHO syndrome: a comparative study with rheumatoid arthritis, ankylosing spondylitis, and healthy controls
BibTeX
@article{falgarone2026fadd,
title = {{FADD Protein for the Early Diagnosis of Rheumatoid Arthritis}},
author = {Géraldine Falgarone and Sara Mouasni and Sylvie Mistou and Valérie Devauchelle-Pensec and Jacques‐eric Gottenberg and Gilles Chiocchia and Léa Tourneur},
journal = {ACR Open Rheumatology},
year = {2026},
month = sep,
doi = {10.1002/acr2.90094},
url = {https://inserm.hal.science/inserm-05769872v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - FADD Protein for the Early Diagnosis of Rheumatoid Arthritis
AU - Géraldine Falgarone
AU - Sara Mouasni
AU - Sylvie Mistou
AU - Valérie Devauchelle-Pensec
AU - Jacques‐eric Gottenberg
AU - Gilles Chiocchia
AU - Léa Tourneur
PY - 2026
DA - 2026/09/06
JO - ACR Open Rheumatology
DO - 10.1002/acr2.90094
UR - https://inserm.hal.science/inserm-05769872v1
AB - Objective FADD (Fas‐Associated Death Domain) protein in patients’ serum and synovial fluid could be a biomarker of inflammation in rheumatic diseases. We tested whether the baseline serum FADD level would be a predictive factor for meeting the American College of Rheumatology (ACR)/EULAR 2010 criteria for rheumatoid arthritis (RA) in order to facilitate the early diagnosis of RA. Methods We measured FADD by enzyme‐linked immunosorbent assay in the sera from 659 patients with early arthritis from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort (at least two swollen joints for more than six weeks and less than six months, no previous exposure to glucocorticoids or disease‐modifying antirheumatic drugs). Patients were eligible for inclusion in the cohort if they had a definitive or probable clinical diagnosis of RA or a diagnosis of undifferentiated arthritis (UA) with a potential for progressing to RA, according to the 2010 ACR/EULAR criteria for RA. Results At inclusion, serum FADD protein was detected in 501 of 659 (76%) patients (range 0–1,503 ng/mL) and levels were independent of patient age and sex. Statistically significant higher levels of FADD were detected in the serum from patients with diagnosed RA at inclusion or who were diagnosed with RA thereafter, than from patients with UA. Receiver operating characteristic curve analysis indicated that a FADD >8 ng/mL had the best sensitivity (50.95%) and specificity (85.71%) for the diagnosis of RA. Moreover, FADD levels were positively associated with anti–citrullinated protein antibody (ACPA), rheumatoid factors, proinflammatory interleukin‐1β (IL‐1β), IL‐6 and IL‐2, and APRIL, a marker of B lymphocyte activation. Conclusion Baseline serum FADD level measurement appeared as a helpful biomarker for the early diagnosis of RA, particularly in patients who were ACPA negative.
SN - 2578-5745
ER -